AstraZeneca, Daiichi’s Enhertu cuts breast cancer progression by 44%
HQ Team June 3, 2025: AstraZeneca and Daiichi Sankyo’s breast cancer drug, Enhertu, has cut the risk of disease progression or death by.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team June 3, 2025: AstraZeneca and Daiichi Sankyo’s breast cancer drug, Enhertu, has cut the risk of disease progression or death by.
HQ Team April 4, 2025: Daiichi Sankyo and AstraZeneca’s treatment for breast cancer, Enhertu, has been approved as a monotherapy in the European.
Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug.
Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development,.
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.
The US regulator has granted a breakthrough therapy designation to British-Swedish AstraZeneca and Japan’s Daiichi Sankyo experimental drug for treating a certain type.
AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.
British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an.
Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a.